Surgical robots allow surgeons to perform a variety of less invasive operations because their miniaturized instruments can work through small incisions in the body and are more dexterous than traditional laparoscopic tools (see “The Slow Rise of the Robot Surgeon”). The result is that patients leave the operating room with a smaller surgical wound with the promise of faster recovery and less scarring.
In 2000, Intuitive Surgical’s da Vinci system became the first FDA-approved commercially available robotic surgical platform and has since been used on hundreds of thousands of patients. According to a report on Bloomberg’s news site, the FDA is now taking another look at the system in response to an increase in reports of adverse incidents. As reported by Bloomberg:
To read the full, original article click on this link: Are Surgical Robots Worth It? | MIT Technology Review
